U.K.’s NICE Clears Lucentis For Treating Diabetic Macular Edema
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s cost-effectiveness agency gave a clear OK to Lucentis as an option for treating visual impairment caused by diabetic macular edema after Novartis provided a bigger price discount and updated analyses showing the drug’s superior relative effect among a sub-group of people with the condition.